201620172018201920202021202220232024Billable/Specific Code
- C7A.8 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2024 edition of ICD-10-CM C7A.8 became effective on October 1, 2022.
- This is the American ICD-10-CM version of C7A.8 – other international versions of ICD-10 C7A.8 may differ.
ICD-10-CM C7A.8 is grouped within Diagnostic Related Group(s):
- 826 Myeloproliferative disorders or poorly differentiated neoplasms with major o. R. Procedures with mcc
- 827 Myeloproliferative disorders or poorly differentiated neoplasms with major o. R. Procedures with cc
- 828 Myeloproliferative disorders or poorly differentiated neoplasms with major o. R. Procedures without cc/mcc
- 829 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures with cc/mcc
- 830 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures without cc/mcc
- 843 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses with mcc
- 844 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses with cc
- 845 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses without cc/mcc
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2016 (effective 10/1/2015): No change
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2024 (effective 10/1/2022): No change
Diagnosis Index entries containing back-references to C7A.8:
- specified NEC > neuroendocrine D3A.8